Lipidomics Reveals Reduced Inflammatory Lipid Species and Storage Lipids after Switching from EFV/FTC/TDF to RPV/FTC/TDF: A Randomized Open-Label Trial
Adrián Curran(Lexington City Schools), Manuel Crespo, Joaquín Burgos, Judit Vidal‐González(Vall d'Hebron Institut de Recerca), Ariadna Torrella(Vall d'Hebron Institut de Recerca), Vicenç Falcó(Universitat Autònoma de Barcelona), Jordi Navarro(Universitat Autònoma de Barcelona), Bibiana Planas(Vall d'Hebron Institut de Recerca), Mario Martín-Castillo(Vall d'Hebron Institut de Recerca), Esteban Ribera(Hospital Terrassa), Joaquim Peraire(Instituto de Salud Carlos III), Anna Rull(Institut de Recerca Biomèdica Catalunya Sud)
Cited by 15
Related Papers
Less Lipoatrophy and Better Lipid Profile With Abacavir as Compared to Stavudine
|JAIDS Journal of Acquired Immune Deficiency Syndromes|2006|137
A Randomized Clinical Trial Comparing Nelfinavir Or Nevirapine Associated to Zidovudine/Lamivudine in HIV-Infected Naive Patients (The Combine Study)
|Antiviral Therapy|2002|137
Resident memory T cells are a cellular reservoir for HIV in the cervical mucosa
|Nature Communications|2019|120
Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study
|The Lancet HIV|2021|110
Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial
|Clinical Infectious Diseases|2017|103